Fate Therapeutics Appoints New Directors, One Resigns
Ticker: FATE · Form: 8-K · Filed: May 31, 2024 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | 8-K |
| Filed Date | May 31, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, management-changes, officer-compensation
TL;DR
Fate Therapeutics adds two directors, loses one. Board shakeup incoming.
AI Summary
On May 30, 2024, Fate Therapeutics, Inc. announced changes in its board of directors. Dr. Paul R. Hastings and Dr. Jeffrey W. Runge have been appointed to the Board, effective May 28, 2024. Concurrently, Dr. Wayne P. Yetman has resigned from the Board. The company also disclosed compensatory arrangements for its officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future decision-making.
Risk Assessment
Risk Level: medium — Board changes can introduce uncertainty about future strategy and leadership direction.
Key Players & Entities
- Fate Therapeutics, Inc. (company) — Registrant
- Dr. Paul R. Hastings (person) — Appointed Director
- Dr. Jeffrey W. Runge (person) — Appointed Director
- Dr. Wayne P. Yetman (person) — Resigned Director
- May 30, 2024 (date) — Report Date
- May 28, 2024 (date) — Effective Date of Appointments
FAQ
Who were the new directors appointed to the Fate Therapeutics Board?
Dr. Paul R. Hastings and Dr. Jeffrey W. Runge were appointed to the Board of Directors.
When were the new directors' appointments effective?
The appointments of Dr. Paul R. Hastings and Dr. Jeffrey W. Runge were effective May 28, 2024.
Who resigned from the Fate Therapeutics Board?
Dr. Wayne P. Yetman resigned from the Board of Directors.
What other information was disclosed in this 8-K filing?
The filing also disclosed compensatory arrangements for certain officers.
What is the principal executive office address for Fate Therapeutics?
The principal executive offices are located at 12278 Scripps Summit Dr., San Diego, CA 92131.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-05-31 17:24:29
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share FATE The Nasdaq
Filing Documents
- d845254d8k.htm (8-K) — 23KB
- 0001193125-24-151963.txt ( ) — 139KB
- fate-20240530.xsd (EX-101.SCH) — 3KB
- fate-20240530_lab.xml (EX-101.LAB) — 17KB
- fate-20240530_pre.xml (EX-101.PRE) — 11KB
- d845254d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Fate Therapeutics, Inc. Date: May 31, 2024 By: /s/ J. Scott Wolchko Name: J. Scott Wolchko Title: President and Chief Executive Officer